NZ535886A - Triazole derivatives as tachykinin receptor antagonists - Google Patents

Triazole derivatives as tachykinin receptor antagonists

Info

Publication number
NZ535886A
NZ535886A NZ535886A NZ53588603A NZ535886A NZ 535886 A NZ535886 A NZ 535886A NZ 535886 A NZ535886 A NZ 535886A NZ 53588603 A NZ53588603 A NZ 53588603A NZ 535886 A NZ535886 A NZ 535886A
Authority
NZ
New Zealand
Prior art keywords
phenyl
trifluoromethyl
benzyl
chloro
bis
Prior art date
Application number
NZ535886A
Other languages
English (en)
Inventor
Albert Kudzovi Amegadzie
Kevin Matthew Gardinier
Erik James Hembre
Jian Eric Hong
Louis Nickolaus Jungheim
Brian Stephen Muehl
David Michael Remick
Michael Alan Robertson
Kenneth Allen Savin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NZ535886A publication Critical patent/NZ535886A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/061,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NZ535886A 2002-04-26 2003-04-22 Triazole derivatives as tachykinin receptor antagonists NZ535886A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37612102P 2002-04-26 2002-04-26
PCT/US2003/010681 WO2003091226A1 (en) 2002-04-26 2003-04-22 Triazole derivatives as tachykinin receptor antagonists

Publications (1)

Publication Number Publication Date
NZ535886A true NZ535886A (en) 2007-07-27

Family

ID=29270766

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ535886A NZ535886A (en) 2002-04-26 2003-04-22 Triazole derivatives as tachykinin receptor antagonists

Country Status (30)

Country Link
US (1) US7320994B2 (enExample)
EP (1) EP1501809B1 (enExample)
JP (1) JP4559087B2 (enExample)
KR (1) KR100755577B1 (enExample)
CN (1) CN1312136C (enExample)
AR (1) AR039329A1 (enExample)
AT (1) ATE384053T1 (enExample)
AU (1) AU2003230829B8 (enExample)
BR (1) BRPI0309534B8 (enExample)
CA (1) CA2483159C (enExample)
CR (1) CR7548A (enExample)
CY (1) CY1107221T1 (enExample)
DE (1) DE60318697T2 (enExample)
DK (1) DK1501809T3 (enExample)
EA (1) EA007720B1 (enExample)
EC (1) ECSP045391A (enExample)
ES (1) ES2298513T3 (enExample)
HR (1) HRP20041008B1 (enExample)
IL (2) IL164675A0 (enExample)
MX (1) MXPA04010622A (enExample)
MY (1) MY141559A (enExample)
NO (1) NO333647B1 (enExample)
NZ (1) NZ535886A (enExample)
PE (1) PE20040600A1 (enExample)
PL (1) PL212090B1 (enExample)
PT (1) PT1501809E (enExample)
TW (1) TWI265807B (enExample)
UA (1) UA79113C2 (enExample)
WO (1) WO2003091226A1 (enExample)
ZA (1) ZA200408670B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
US20060160794A1 (en) * 2003-06-12 2006-07-20 Amegadzie Albert K Tachykinin receptor antagonists
PT1675846E (pt) * 2003-10-24 2010-04-20 Lilly Co Eli Novas formas cristalinas de {2-[1-(3,5-bis-trifluorometilbenzil)-5- iridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona
CA2581454A1 (en) 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
WO2006083711A1 (en) * 2005-02-01 2006-08-10 Eli Lilly And Company Tachykinin receptor antagonists
JP4874958B2 (ja) 2005-03-30 2012-02-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピリジン誘導体を含有する抗真菌剤
TW200716576A (en) * 2005-06-07 2007-05-01 Shionogi & Co Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
DE602006018149D1 (de) * 2005-07-25 2010-12-23 Hoffmann La Roche Substituierte triazolderivate und ihre verwendung als antagonisten des neurokinin-3-rezeptors
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
MX2009001710A (es) * 2006-08-18 2009-02-25 Syngenta Ltd Uso de inhibidores hppd para el tratamiento de la depresion y/o sindrome de abstinencia asociados con drogas adictivas.
EP2065377B1 (en) 2006-09-21 2011-11-23 Eisai R&D Management Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
EP2121610B1 (en) 2006-12-20 2014-04-02 Eli Lilly & Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
MX2010001135A (es) * 2007-08-08 2010-03-09 Neurosearch As Nuevos derivados de 1,2,3-triazol, utiles como modulares de receptores de acetilcolina nicotinicos.
GB0722077D0 (en) 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
WO2009158011A1 (en) * 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
GB0823002D0 (en) * 2008-12-17 2009-01-28 Syngenta Participations Ag Isoxazoles derivatives with plant growth regulating properties
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
BR112017018620A2 (pt) 2015-03-04 2018-04-17 Vanda Pharmaceuticals Inc. método de administração de tradipitanto, e, tradipitanto.
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
SG10201913616UA (en) 2016-05-31 2020-03-30 Kalvista Pharmaceuticals Ltd Pyrazole derivatives as plasma kallikrein inhibitors
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
CA3073998A1 (en) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
CN119074729A (zh) * 2017-11-17 2024-12-06 万达制药公司 使用川地匹坦治疗胃肠疾病的方法
MX2020005168A (es) 2017-11-29 2020-08-20 Kalvista Pharmaceuticals Ltd Formas de dosificacion que contienen un inhibidor calicreina de plasma.
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
ES2980110T3 (es) 2018-02-26 2024-09-30 Ospedale San Raffaele Srl Antagonistas de NK-1 para uso en el tratamiento del dolor ocular
JP7410137B2 (ja) * 2018-06-08 2024-01-09 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントを用いる処置方法
EP3856338B1 (en) * 2018-09-28 2024-11-06 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2020132513A1 (en) 2018-12-21 2020-06-25 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2021173641A1 (en) 2020-02-25 2021-09-02 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
EP4117673A1 (en) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Treatment of stem cell deficiency
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
EP4125875A1 (en) 2020-04-03 2023-02-08 NeRRe Therapeutics Limited An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
CN113563306B (zh) * 2020-04-28 2022-07-01 新发药业有限公司 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法
KR20230018485A (ko) 2020-06-02 2023-02-07 네르 쎄라퓨틱스 리미티드 폐에 대한 기계적 손상에 의해 촉진된 폐 섬유증 상태의 치료에 사용하기 위한 뉴로키닌 (nk)-1 수용체 길항제
CN111662235B (zh) * 2020-06-23 2023-12-22 黄淮学院 一种苯甲酰基哒嗪衍生物及其制备方法
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2024138040A1 (en) 2022-12-21 2024-06-27 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
CN116082253B (zh) * 2023-02-25 2025-04-25 浙大城市学院 一种1-n-取代的1,2,3-三唑-4-甲酰胺衍生物及其制备方法
WO2024223617A1 (en) * 2023-04-24 2024-10-31 Fundamental Pharma Gmbh Effective means to modulate nmda receptor-mediated toxicity
US20250255855A1 (en) 2024-02-09 2025-08-14 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50699A0 (en) 1975-10-28 1976-12-31 Ici America Inc Triazole derivatives
WO1995011880A1 (en) * 1993-10-27 1995-05-04 Merck Sharp & Dohme Limited Substituted amides as tachykinin antagonists
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
US5998444A (en) 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
AU2633897A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Solid phase and combinatorial synthesis of substituted 1,2,3-triazoles and of arrays of substituted 1,2,3-triazoles
EP0915880B1 (en) 1996-07-24 2007-10-10 Bristol-Myers Squibb Pharma Company Azolo triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
EP1005454A4 (en) 1997-08-06 2003-01-15 Lilly Co Eli 2-ACYLAMINOPROPANAMINE FOR USE AS TACHYKININ RECEPTOR ANTAGONISTS
EP1237874B1 (en) 1999-12-17 2006-02-22 Schering Corporation Selective neurokinin antagonists
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
DE10036818A1 (de) * 2000-07-28 2002-02-07 Solvay Pharm Gmbh Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
JP2002123925A (ja) 2000-10-13 2002-04-26 Fuji Photo Film Co Ltd 磁気記録媒体
DK1501808T3 (da) * 2002-04-26 2008-10-13 Lilly Co Eli Tachykininreceptor-antagonister

Also Published As

Publication number Publication date
NO333647B1 (no) 2013-07-29
UA79113C2 (en) 2007-05-25
EP1501809A1 (en) 2005-02-02
HRP20041008B1 (hr) 2012-10-31
AU2003230829A1 (en) 2003-11-10
HK1073304A1 (en) 2005-09-30
DK1501809T3 (da) 2008-05-13
EA200401431A1 (ru) 2005-06-30
WO2003091226A1 (en) 2003-11-06
BRPI0309534B8 (pt) 2021-05-25
TWI265807B (en) 2006-11-11
TW200306824A (en) 2003-12-01
ATE384053T1 (de) 2008-02-15
HRP20041008A2 (en) 2004-12-31
AU2003230829B2 (en) 2008-12-04
DE60318697T2 (de) 2009-01-08
PL212090B1 (pl) 2012-08-31
CA2483159C (en) 2010-08-10
PL373504A1 (en) 2005-09-05
DE60318697D1 (de) 2008-03-06
PT1501809E (pt) 2008-03-18
KR100755577B1 (ko) 2007-09-12
CA2483159A1 (en) 2003-11-06
EA007720B1 (ru) 2006-12-29
CN1312136C (zh) 2007-04-25
IL164675A0 (en) 2005-12-18
BR0309534A (pt) 2005-02-01
US7320994B2 (en) 2008-01-22
NO20045120L (no) 2004-12-07
MXPA04010622A (es) 2005-01-25
CN1646502A (zh) 2005-07-27
CR7548A (es) 2006-12-01
BRPI0309534B1 (pt) 2017-11-07
MY141559A (en) 2010-05-14
JP2005536458A (ja) 2005-12-02
JP4559087B2 (ja) 2010-10-06
IL198122A0 (en) 2009-12-24
PE20040600A1 (es) 2004-09-15
ECSP045391A (es) 2005-01-03
ES2298513T3 (es) 2008-05-16
KR20040104634A (ko) 2004-12-10
CY1107221T1 (el) 2012-11-21
EP1501809B1 (en) 2008-01-16
US20050239786A1 (en) 2005-10-27
AU2003230829B8 (en) 2008-12-11
ZA200408670B (en) 2005-10-26
AR039329A1 (es) 2005-02-16

Similar Documents

Publication Publication Date Title
CA2483159C (en) Triazole derivatives as tachykinin receptor antagonists
CA2484188C (en) Tachykinin receptor antagonists
US8163756B2 (en) Enzyme modulators and treatments
JP5378532B2 (ja) 複素環γ−セクレターゼモジュレーター
US11168079B2 (en) Alkene compounds as farnesoid x receptor modulators
JP2001525802A (ja) GABAα5リガンドとしての置換1,2,4−トリアゾロ[3,4−a]フタラジン誘導体
US8404672B2 (en) Substituted heterocyclic compounds
US11370785B2 (en) Multicyclic compounds as farnesoid X receptor modulators
JP2001503408A (ja) GABA▲下A▼α5受容体サブタイプに対するリガンドとしてのチエニルシクロヘキサノン誘導体
HK1073304B (en) Triazole derivatives as tachykinin receptor antagonists
AU2003224868B8 (en) Tachykinin receptor antagonists

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed